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Adipose-derived stem cell (AD-MSC)Musculoskeletal disorders represent a major cause of disability and morbidity globally and result in enor-
mous costs for health and social care systems. Development of cell-based therapies is rapidly proliferat-
ing in a number of disease areas, including musculoskeletal disorders. Novel biological therapies that can
effectively treat joint and spine degeneration are high priorities in regenerative medicine. Mesenchymal
stem cells (MSCs) isolated from bone marrow (BM-MSCs), adipose tissue (AD-MSCs) and umbilical cord
(UC-MSCs) show considerable promise for use in cartilage and intervertebral disc (IVD) repair. This
review article focuses on stem cell-based therapeutics for cartilage and IVD repair in the context of the
rising global burden of musculoskeletal disorders. We discuss the biology MSCs and chondroprogenitor
cells and specifically focus on umbilical cord/Wharton’s jelly derived MSCs and examine their potential
for regenerative applications. We also summarize key components of the molecular machinery and sig-
naling pathways responsible for the control of chondrogenesis and explore biomimetic scaffolds and bio-
materials for articular cartilage and IVD regeneration. This review explores the exciting opportunities
afforded by MSCs and discusses the challenges associated with cartilage and IVD repair and regeneration.
There are still many technical challenges associated with isolating, expanding, differentiating, and
pre-conditioning MSCs for subsequent implantation into degenerate joints and the spine. However, the
prospect of combining biomaterials and cell-based therapies that incorporate chondrocytes, chondropro-
genitors and MSCs leads to the optimistic view that interdisciplinary approaches will lead to significant
breakthroughs in regenerating musculoskeletal tissues, such as the joint and the spine in the near future.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Age-related musculoskeletal disorders represent a major cause
of morbidity globally and result in enormous costs for health and
social care systems. Chronic and inflammatory diseases of joints
and the spine, including osteoarthritis (OA) and low back pain
(LBP) caused by intervertebral disc (IVD) degeneration respec-
tively, are major causes of disability in the elderly. With increases
in life expectancy, the burden of musculoskeletal disorders will
unavoidably and progressively grow. The increase in muscu-
loskeletal disability among the ageing population highlights an
acute and urgent need for a radical shift in healthcare strategies
that involve lifestyle interventions that can prevent these disorders
and novel pharmacological and biological therapies that can effec-
tively treat them. Development of cell-based therapies is rapidly
proliferating in a number of disease areas, including musculoskele-
tal disorders. Autologous chondrocyte implantation (ACI) has been
used for treatment of osteoarticular lesions for over two decades.
Although chondrocyte-based therapy has the capacity to slow
down the progression of OA and delay partial or total joint replace-
ment surgery, currently used procedures are associated with the
risk of serious adverse events. Therefore there is significant interest
in improving the success rate of ACI by improving surgical tech-
niques and preserving the phenotype of the primary chondrocytes
used in the procedure. Likewise, disc cell re-implantation has been
trialed for the treatment of IVD degeneration and LBP, as has allo-
geneic juvenile chondrocyte implantation [1,2]; however while
these therapies showed promising outcomes a number of hurdles
prevent their widespread clinical adoption. As a result of the limi-
tations of chondrocyte re-implantation-based therapies, experi-
mental therapies using stem cells are receiving an increasing
amount of scientific and public interest. Mesenchymal stem cells
(MSCs) show considerable promise for use in cartilage and IVD
repair and are being clinically explored as a new therapeutic for
treating a variety of other immune mediated diseases. MSCs have
potential applications in tissue engineering and regenerative med-
icine and may represent an attractive option for repairing focal
lesions in cartilage and IVD degeneration [3]. Future tissue-
engineering approaches for cartilage and IVD repair will benefit
from advances in MSC-based repair strategies. This review article
focuses on stem cell-based therapeutics for cartilage and IVDrepair in the context of the rising global burden of musculoskeletal
disorders. We explore the exciting opportunities afforded by MSCs
and discuss the challenges associated with cartilage and IVD repair
and regeneration by combining biomaterials and cell-based
therapies with chondrocytes and MSCs. We also highlight several
new areas for future investigation.
2. Stem cells in regenerative medicine
Stem cell-based therapies that integrate tissue-engineering
technologies and biomaterials science are fundamental pillars of
the science of regenerative medicine. Clinical success with
hematopoietic stem cell transplantation for leukemia/lymphoma
is very well established and has been clinically validated, thus pro-
viding a strong foundation for the establishment of stem cell-based
therapeutics. However, the clinical outcomes of stem cell trans-
plantation for other diseases remain poor and this prompts us to
debate whether we should use stem cells or their biological deriva-
tives. Therefore, there is always a continuous search for cells/stem
cells with better safety and effective differentiation capacity to
replace or restore function to damaged tissues and organs.
Researchers today have access to a plethora of stem cells with
varying potencies, viz. pluripotent (tri-lineage – ESCs, iPSCs)
[4,5], multipotent (more than one lineage – adult and fetal tissue
specific MSCs including bone-marrow, adipose tissue, amnion,
umbilical cord), and unipotent (single lineage – hematopoietic
stem cells) [6–10]. Choosing the right stem cell is imperative for
obtaining favorable results in regenerative medicine. Since many
recent reviews including some of our own papers [3,11,12] have
already discussed the potential of BM-MSCs and AD-MSCs in
regenerative medicine, in this review we have focused specifically
on umbilical cord/Wharton’s jelly MSCs (UC-MSCs/WJMSCs).
3. Cartilage degeneration and current management strategies
for OA
The ageing population (>60 years) is predicted to expand signif-
icantly by the year 2050, reaching well over 2 billion people
globally [13,14]. This growing geriatric population will lead to
an increase in all age related diseases, including OA. Articular
lesions either due to OA or traumatic injuries is associated with
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tion, pain, joint effusion and disability and this clinical problem
still remains unresolved and poses a major challenge [15–17].
Age related ’wear and tear’, chondrocytes’ poor response to growth
factors, altered bio-mechanical properties of articular cartilage,
mitochondrial dysfunction, oxidative stress and inflammation are
all implicated in the pathogenesis of OA, highlighting the multifac-
torial and complex nature of this degenerative joint disease [18].
Eventual decreases in the number of chondrocytes with age results
in impaired production of extracellular matrix proteins. In addi-
tion, while progenitor cells have been identified in articular carti-
lage [19,20], the tissue displays an extremely limited natural
healing capacity [18], due in part to its hypocellularity and to a lack
of vasculature. An articular lesion can be either a focal defect in the
cartilage surface or extensive cartilage degradation and therefore
the treatment needs to be tailored. Pharmacological management
with disease modifying osteoarthritis drugs (DMOADs), natural
remedies, weight reduction and mild exercises, help relieve pain to
some degree, but does not offer a disease cure [21]. Various surgical
methods have been attempted to restore the damaged cartilage and
improve joint function, such as microfracture, subchondral drilling
and abrasion arthroplasty. These techniques are aimed to promote
intrinsic healing by promoting vascular invasion, fibrin clot forma-
tion and recruitment of stem cells [16]. However, poor biomechani-
cal properties of the tissue in microfracture, as well as donor site
morbidity (which may result in substantial impairment for patients),
low cellularity and surrounding cartilage damage limit their uses
and moreover, long term efficacy is not known [16,22,23].
When pharmacological and surgical management strategies fail
(which they often do) the disease progresses to end stage OA, where
joint arthroplasty may become the only definitive and unavoidable
option. However, the limited lifespan of currently available prosthe-
ses cannot cope with the demands of younger and more active
patients. These harsh surgical realities present new opportunities
for the development of future therapeutics including stem
cell-based therapies. Stem cells have been used to restore damaged
myocardium, spinal cord, brain, liver, retina and skin [24–27].
Regenerative medicine thus offers a significant therapeutic potential
and could provide an excellent alternative to arthroplasty.
4. Cell-based therapies for cartilage regeneration
As discussed earlier, the use of autologous chondrocyte implan-
tation (ACI), autologous matrix induced chondrogenesis (AMIC)
and intra-articular injection of meniscus stem/progenitors cells
[16,23,28–30] represent the current state-of-the-art in this area.
MSC-based cell therapy is beginning to show some promising
results. Considerable pain relief and improvement in the pain on
visual analog scale were reported in four patients with severe
OA, following injection of autologous BM-MSCs (8–9  106 cells/-
patient) into the knee joint that was most affected [31]. Likewise,
administration of allogeneic MSCs (40  106 cells) in OA patients
showed improvement in the articular cartilage quality as assessed
by magnetic resonance imaging (T2 mapping) compared to those
patients that received single intra-articular injection hyaluronic
acid (60 mg) injections indicating that allogeneic MSCs could be
an alternative source [32]. Thus, resident progenitor cells, as well
as both autologous and allogeneic stem cells derived from various
sources (viz. bone marrow, synovium, adipose tissue etc.) have
been used for the treatment of OA with variable success either as
direct injections into the damaged site or following differentiation
into cartilage together with tissue engineered scaffolds or follow-
ing treatment with growth factors [33,34]. Growth factors, cytoki-
nes, bioactive lipids, micro-vesicles that are released from
implanted stem cells may also exert beneficial effects including
anti-inflammatory, angiopoietic and apoptotic effects. Thereforethe observed improvements in pain relief and function may be in
fact due to paracrine effects of injected MSCs, indicating that bio-
logical products secreted by stem cells rather than the cells them-
selves could potentially be used as therapeutic agents.
4.1. Molecular control of chondrogenesis
Understanding the regulation of normal skeletogenesis is of
great importance in the context of cartilage regenerative medicine
because cell-based regeneration techniques recapitulate, at least in
part, the main developmental steps that occur in vivo. Understand-
ing the mechanisms and the machinery responsible for regulating
chondrogenesis will enhance regenerative medicine. Chondrogen-
esis commences with the recruitment, migration, and proliferation
of chondroprogenitors during the early phase of embryonic skele-
togenesis [35]. At this stage, the chondroprogenitor cells produce
an extracellular matrix (ECM) rich in hyaluronan, collagen type I,
and the alternatively spliced long form of collagen type IIA contain-
ing an amino-propeptide encoded by exon 2 [36]. Aggregation into
precartilage condensations is mediated by the appearance of cell–
cell interactions (via N-cadherin), gap junctions, and cell adhesion
molecules (N-CAM) [37]. These interactions, along with fibronec-
tin, tenascins and thrombospondins deposited in the ECM, trigger
intracellular signaling cascades that allow the differentiating chon-
droprogenitor cells to acquire the typical spherical morphology of
chondrocytes and initiate synthesis of cartilage-specific ECMmole-
cules such as collagen types IIB, IX, and XI, and aggrecan [37].
The HMG-box transcription factor Sox9, one of earliest markers
of chondrogenic cells, is essential for the expression of collagen
type II (Col2a1) and other ECM proteins such as Col11a2 and CD-
RAP [38]. Sox9 acts in cooperation with two additional Sox family
members, L-Sox5 and Sox6, which contain no transcriptional acti-
vation domain, and are required for the expression of Col9a1,
aggrecan, and link protein [38]. One of the upstream mediators
of Sox9 is hypoxia-inducible factor-2a (HIF-2a) which promotes
the upregulation of cartilage ECM genes [39]. Besides Sox proteins,
the Runt-related transcription factor Runx2 is also expressed in
chondrogenic cells; furthermore, other transcription factors,
including Barx2, Nkx3.2/Bapx1, Msx1 and 2, b-catenin, Smads,
Lef1, AP-1 and AP-2, are also known to control chondrogenic differ-
entiation (reviewed in [40–42]).
A number of extracellular signaling molecules and growth fac-
tors, including various members of the fibroblast growth factor
(FGF), hedgehog, transforming growth factor-b (TGF-b) and bone
morphogenic protein (BMP), platelet-derived growth factor (PDGF),
insulin-like growth factor (IGF), epidermal growth factor (EGF) fam-
ilies; retinoic acid (RA), as well as wingless/Int (Wnt) glycoproteins
are all important regulators of prechondrogenic cell condensation
and chondrogenic differentiation (reviewed in [37,42]). The prolif-
eration rate of progenitor cells during chondrogenesis is determined
by the balance of signaling by BMPs and FGFs; themitogenic stimuli
converge on the cyclin D1 gene [43]. The glucocorticoid dexametha-
sone is known to enhance cartilage-specific gene expression in TGF-
b3 induced MSC cultures [40].
A considerable amount of data has been published concerning
cytoplasmic signaling pathways that relay extracellular stimuli to
gene expression. Various members of the TGF-b superfamily are
strong inducers of chondrogenesis; TGF-b1 and TGF-b3 are more
potent mediators than TGF-b2 [40]. BMP signaling is essential for
chondrogenic differentiation [44] as the expression of Sox proteins
is dependent upon BMP signaling via the Ser/Thr kinase receptors
ALK3 (BMPR1A) and ALK6 (BMPR1B) [45], mediated by the canon-
ical Smad pathway; the phosphorylated Smads form complexes
with Smad4, translocate to the nucleus, and bind to SMAD ele-
ments in the promoters of target genes such as Sox9, Col2a1, and
Runx2 [46,47]. Among BMPs, BMP-2 has been shown to possess
Fig. 1. Schematic summarizing the key stages of chondrogenic differentiation including the transcription factors, signaling molecules and protein kinases/phosphoprotein
phosphatases involved.
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lates ECM synthesis and at the same time inhibits catabolic factors
[48]. Through an alternative (Smad-independent) pathway, BMPs
can also activate the mitogen-activated protein kinase (MAPK) sig-
naling route by triggering MEKK1 and subsequently p38 and c-jun
N-terminal kinase (JNK) cascades, or by activating the Ras/ERK1/2
or RhoA/ROCK axis [44,47]. Of the three main MAPK pathways, p38
and ERK1/2 have been described as key regulators of chondrogenic
differentiation; the p38 pathway is primarily involved in the
initiation of condensation, and ERK1/2 activation interacts with
BMP-2-induced signaling to promote chondrogenesis [41]. Down-
stream MAPK signaling results in the activation of target transcrip-
tion factors including AP-1, ETS, Runx2, HIF-2a, and C/EBPb [39]. In
BM-MSCs, all three MAPKs were found to be positive transducers
in TGF-b1-induced chondrogenesis by promoting cell adhesion
through elevated N-cadherin levels [41].
Besides MAPK cascades, virtually all major members of Ser/Thr
protein kinases including protein kinase A (PKA) [49], PKC
(reviewed by [50]) and Rho kinases (ROCKI and II) [40], as well
as phosphoprotein phosphatases such as PP1, PP2A and calcineurin
(reviewed by [51]) have been well documented as key regulators of
chondrogenesis, with either stimulatory or inhibitory effects. The
Notch pathway is also active during the early stages of chondroge-
nesis. The roles of Notch receptors (Notches 1–4) and the Notch
ligands (Jagged-1, Jagged-2, DLL-1, DLL-3 and DLL-4) have all been
investigated in this context. Interestingly, while a transient Notch
signaling was found to be necessary at the beginning of chondro-
genic differentiation of MSCs, it has to be switched off at subse-
quent stages [52]. The schematic shown in Fig. 1 summarizes the
key stages of chondrogenic differentiation including the transcrip-
tion factors, signaling molecules and protein kinases/phosphopro-
tein phosphatases involved.
While collagen type II is the major structural collagen in carti-
lage ECM, MSCs cultured in chondrogenic conditions maintain col-
lagen type I secretion, accompanied by upregulation of Col10a1 in
parallel with gradual downregulation of Col2a1 toward later stages,
suggesting that they do not halt their initial programme and
undergo hypertrophy [52]. To avoid hypertrophic differentiation,strategies based on the use of molecules with an inhibitory effect
on growth plate development have been developed; indeed, PTHrP
(parathyroid hormone related peptide) or FGF-2 are known to down-
regulate col10a1, but also col2a1, during in vitro chondrogenesis of
adult MSCs [53]. The main challenge of cartilage regeneration tech-
niques, therefore, is to ensure appropriate differentiation and matrix
synthesis by MSCs and thus avoid production of a fibrocartilage, or
progression to hypertrophic cartilage which may eventually ossify.
4.2. Wharton’s Jelly stem cells (WJSCs): a promising source of MSCs for
regenerative medicine
Despite the presence of many different types of stem cells, in
recent years UC-MSCs have gained much attention as being a
potential cell source for tissue engineering and regenerative med-
icine. These MSCs were first isolated in 1991 by McElreavey and
colleagues [10]. Since then significant effort has been devoted to
the refinement of methods for their isolation, characterization
and functional evaluation in an attempt to find an alternative
source of stem cells to keep pace with the growth and demands
of regenerative medicine. MSCs have been isolated from various
zones within the umbilical cord [54], including the subendothelial
layer [55]; perivascular zone [56], Wharton’s jelly [57], umbilical
cord lining [58] and the whole umbilical cord [59]. MSCs isolated
from within the various regions of the umbilical cord fulfill the
stipulated minimum criteria of ‘plastic adherence’, ‘immunological
profile’ and ‘differentiation’ as stated in the position paper of the
International Society for Cellular Therapy [60]. The yield of MSCs
from within the Wharton’s jelly (WJSCs) is high compared to other
zones in the umbilical cord (Fig. 2). In addition, WJSCs has several
advantages that make them an attractive choice for use in tissue
engineering and regenerative medicine. WJSCs (i) are a relatively
young cell type compared to most other MSCs, (ii) have no ethical
concerns unlike ESCs, (iii) can be harvested painlessly unlike bone-
marrowMSCs, (iv) share few embryonic features, (v) have high cell
proliferation, (vi) have wide differentiation potential, (vii) are
hypo-immunogenic and (viii) are non-tumorigenic [61–67]. Devel-
opmentally, the umbilical cord and its contents are embryonic in
Fig. 2. Umbilical cord-Wharton’s Jelly stem cells (WJSCs) for cartilage or IVD regeneration: (A) human umbilical cord (10 cm); (B) sectioned pieces of umbilical cord (2 cm
each); (C) each piece opened longitudinally; (D) blood vessels removed from sections of the umbilical cord; (E) the sectioned pieces (with opened side down in contact with
the Petri dish were treated with an enzymatic cocktail) for 45 min at 37 C; loosened Wharton’s Jelly was gently scraped into the medium, centrifuged at 300g  5 min; pellet
resuspended in culture medium comprising (DMEM high glucose, 20% fetal bovine serum, basic fibroblast growth factor 16 ng/ml, 2 mM L Glutamine, insulin-transferrin-
selenium and antimycotic-antibiotic); derived WJSCs were characterized using FACS (presence of MSC related CD markers) and tri-lineage differentiation. (F) Phase contrast
image of Wharton’s Jelly stem cells showing characteristic short fibroblastic cells; (G) Electrospun biodegradable nanofibrous scaffold; (H) Cells together with growth factors
or platelet rich plasma. Useful applications include either (i) use of WJSCs alone; (ii) following culture on scaffolds (with or without differentiation media) or (iii) cells
together with growth factors or platelet rich plasma.
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three primordial germ layers, the amnion and the allantois.
Therefore, WJSCs come to occupy an intermediate position
between the most versatile pluripotent ESCs/iPSCs and adult tissue
specific MSCs, which might explain the presence of some embry-
onic stem features and increased stemness [63,68].
4.3. Articular cartilage tissue engineering: challenges and prospects
Cartilage is avascular and is plagued by slow repair processes
following injury. Chondrocytes are the only cell type in the carti-
lage and with age the proportion of senescent cells within the tis-
sue increases. These senescent cells have been shown to adopt a
more catabolic senescence-associated secretory phenotype (SASP),
which is characterized by increased secretion of catabolic cytoki-
nes and matrix degrading enzymes [12,69], potentially limiting
the number of cells suitable for use regenerative therapies. There-
fore, there exists a great dependence on other sources of cells/stem
cells that can efficiently undergo chondrogenic differentiation. Car-
tilage tissue engineering is rapidly emerging as a promising poten-
tial cure for articular cartilage lesions and this in turn has
intensified the screening of many different types of stem cells. Irre-
spective of the cell source, MSCs have been demonstrated to
undergo chondrogenic differentiation upon stimulation with
inductive agents including transforming growth factor beta and
bone morphogenetic proteins, insulin-like growth factors,
insulin-transferrin-selenium and hepatocyte growth factor [70].
As ageing MSCs have reduced chondrogenic potential [71], use of
adult tissue specific MSCs in cartilage regeneration will have lim-
ited benefits. Lack of significant cell numbers has always been a
limiting factor in tissue engineering and regenerative medicine.
Cartilage is mainly composed of collagen and proteoglycans thatmainly help maintain the biomechanical properties. Maintaining
phenotypic stability and biomechanical properties following differ-
entiation is a great challenge, as these characteristics tend to
change over time. With most MSCs there could occur a transition
in production of type I collagen rather than the desired type II col-
lagen and this might lead to development of a fibrocartilage [72]
with a poor therapeutic outcome.
WJSCs, by their inherent nature have high hyaluronic acid, sul-
fated glycosaminoglycans (GAGs) and collagen expression [73],
which to some extent reflect native cartilage tissue. Moreover, uses
of WJSCs following their differentiation into multiple cell types as
reported by many different research groups, with some progress-
ing on to clinical trials is encouraging [74–76] and justify the use
of WJSCs in cartilage regeneration procedures. Persistence of B7
family co-stimulator immune molecule B7-H3 (CD276) in the
undifferentiated and chondrogenic differentiated cells, indicate
that WJSCs will continue to have immune privilege [77] which is
another added advantage. High density WJSC cultures using rotary
cell culture system enabled development of soft, opaque non-
scaffold cartilage-like tissue which was larger than the conven-
tional pellet cultures and also showed high expression of GAG
and collagen II [78]. However, compared to two-dimensional
(2D) cultures, three-dimensional (3D) systems that closely mimic
the native tissue are hoped to improve transplant outcomes.
Marked chondrogenic differentiation is reported following culture
of WJSCs in 3D electrospun nanofibrous scaffolds [79], collagen
hydrogels [65] and poly-e-caprolactone (PCL)/collagen nanoscaf-
folds [63]. Expression of collagen and GAGs were much higher than
BM-MSCs and genes related to chondrogenic differentiation
including SOX9, collagen type II and cartilage oligomeric matrix
protein (COMP) were also highly expressed following culture of
WJSCs on nanoscaffolds [63]. The fact that articular cartilage has
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bearing function, it is pertinent that suitable tissue engineering
material and an appropriate cell type be used in cartilage regener-
ation. Synthetic polymers are widely used in tissue engineering as
they have excellent three dimensionality, porosity, biomechanical
and biodegradable properties. Poly (lactide-co-glycolide) (PLGA)
is approved by the FDA and it has been extensively used in liga-
ment, tendon, cartilage and bone regeneration. WJSCs seeded on
electrospun scaffold prepared by combination of PLGA, hydroxyap-
atite and zein facilitated cartilage regeneration in an in vivo rabbit
model with a chondral defect [80]. The cross talk between cartilage
and the subchondral bone indicate that for effective cartilage
repair it would be best to consider scaffolds that would aid
cartilage-bone differentiation. The use of human telomerase
reverse transcriptase (hTERT) to prolong the life span of stem cells
and prevent replicative senescence is yet another strategy [81] to
meet the desired cell numbers. However, preclinical studies with
long-term follow-up are necessary to rule out development of
any tumors before moving on to human applications.
In summary, WJSCs could be derived in abundance to meet the
growing demand of tissue engineering and regenerative medicine
that would help cure many diseases including chondral or osteo-
chondral defects. They have several advantages over other existing
MSCs and could be used effectively in translational research.
Emerging developments and improvisations in tissue engineering
technologies combined with use of the right stem cells/stem cell
derivatives as WJSCS, will hopefully lead to the much-anticipated
advancements in regenerative medicine in the near future.5. Back pain and intervertebral disc (IVD) degeneration
Low back pain (LBP) is one of the leading causes of disability in
the developed world, with lifetime prevalence estimated at over
80% [82]. As with many other musculoskeletal disorders, including
OA, the prevalence of LBP increases with age [83], suggesting inci-
dence is likely to increase due to a global aging population, changes
in lifestyle and occupational stresses [84]. The global economic
burden of LBP is significant and alarming. The total cost of back
pain in the UK is estimated to be between 1% and 2% of gross
domestic product (GDP), equating to between £14 and £28 billion
lost per annum [http://www.backcare.org.uk/factsandfigures];
[85], while in the United States costs have been estimated at
around $85.9 billion [86].
LBP is a complex and multifactorial entity, encompassing
mechanical, physiological and psychosocial dimensions [87].
Genetic predisposition and environmental factors, including smok-
ing, obesity and abnormal mechanical loading, have been impli-
cated in the pathogenesis of LBP [82,88–92]. Stress has also been
implicated as a modifiable risk factor for persistent and non-
persistent LBP [93]. However, there is increasing evidence,
obtained through imaging studies, to suggest that a significant pro-
portion of LBP is associated with degeneration of the intervertebral
disc (IVD) [94,95], and direct clinical evidence implicating disc
space narrowing (which develops with progression of IVD degener-
ation) with chronic LBP [96–98]. Studies have also demonstrated a
potential direct mechanistic association between degeneration and
LBP, with increased nociceptive nerve ingrowth occurring in the
painful degenerate IVD [99].
Magnetic resonance imaging (MRI) scanning is a non-invasive
commonly used diagnostic modality for the assessment of degen-
erative disc disease. This sensitive tool provides accurate morpho-
logic information regarding the disc and can influence clinical
making decisions [87,100,101]. Conventional T2 weighted sagittal
MRI sequences have been utilized to create a subjective grading
scale for disc health based on morphological features [102].IVD degeneration may initially start as a silent and therefore
sub-clinical process. There is a spectrum of degeneration occurring
over many years, which starts with a healthy disc and which can
end with a bone-on-bone appearance with near total obliteration
of the disc space. For clinicians investigating and treating LBP,
the challenge has been to ascertain the duration and degree of
symptoms and loss of function a patient has, before embarking
on treatment.
Once symptomatic degenerative disc disease has been diag-
nosed, a multitude of treatment strategies exist ranging from con-
servative treatment and physical/behavioral therapy, through to
spinal corticosteroid injections and more invasive options such as
minimally invasive and open surgeries with or without insertion
of implants to either replace the disc or restrict motion or fuse
the motion segment. Treatments ranging from physiotherapy to
osteopathy may be provided by different healthcare professionals
including physicians, pain specialists and spinal surgeons. There
is certainly no universal agreement regarding the management of
degenerative spine conditions.
Unfortunately, while a wide range of treatments are available,
they offer only short-term relief, and are often accompanied by loss
of function, mobility, and altered spinal biomechanics leading to
disc degeneration at adjacent levels and further pain [103–105].
Given these limitations, current research is now concentrating on
the development of more biological/regenerative therapies to tar-
get the underlying pathogenesis to repair the IVD or prevent
degeneration.
5.1. The biology of IVD degeneration
The IVD is vital to the flexibility and mechanical integrity of the
spine by virtue of the opposing forces generated by its two main
components; the central hydrophilic, proteoglycan (particularly
aggrecan) and type II collagen-rich nucleus pulposus (NP), and
the peripheral fibrous, type I collagen-rich annulus fibrosus (AF).
In recent years the pathogenesis of IVD degeneration has been elu-
cidated, with studies implicating aberrant disc cell function in its
pathophysiology [106–114]. With degeneration, NP cells demon-
strate increased expression of a range of pro-inflammatory/
catabolic cytokines and inflammatory mediators, including IL-1,
IL-6, IL-12 IL-17, TNF-a and IFN-c [115]. Most notably, elevated
expression of IL-1 by disc cells from degenerate tissue leads to
the production of inappropriate matrix and increased matrix
degrading enzyme expression by native disc cells [106,108].
Increased TNF-a expression in degenerate tissue [116,117] is also
thought to be involved in upregulating matrix degrading enzymes
[117] and stimulating nerve ingrowth, suggesting a potential role
in innervation and development of discogenic pain [118]. IVD
degeneration is thought to originate in the NP, where there is a loss
of normal matrix, with increased Matrix Metalloproteinase (MMPs
1, 3, 7, 9, 10 and 13), and A Disintegrin And Metalloproteinase with
Thrombospondin Motifs (ADAMTS 1, 4, 5, 9 and 15) activity being
responsible for matrix catabolism [107,112–114]. There is also a
shift from type II to type I collagen expression by NP cells and a
decrease in aggrecan synthesis, leading to dehydration of the
matrix in the NP [112]. Dehydration leads to the loss of swelling
pressures responsible for maintaining mechanical integrity, ulti-
mately leading to local spinal instability and mechanical trauma.
In parallel, the diminished aggrecan and increased catabolic cyto-
kine levels, allows the in-growth of neurites, resulting in pain
[99,119,120].
5.2. Novel therapies for IVD degeneration
None of the current surgical methods address the aberrant
cytokine-rich/pro-inflammatory milieu of the degenerate IVD, or
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IVD. Consequently, research has focused on the development of
biological therapies and regenerative approaches. Application of
biological therapy is intended to inhibit the abnormal cytokine
production, or stimulate matrix anabolism. Platelet-rich plasma
contains growth factors and has been shown to induce annulus
fibrosus cell proliferation and matrix production [121]. Further-
more injection of platelet-rich plasma into rat and rabbit IVD
degeneration models has demonstrated that it may act to delay
progression of early stage disease [122,123], although its ability
to regenerate tissue is yet to be elucidated. Anabolic growth factors
(including TGF-b, IGF-1, OP-1, GDF5 and GDF6) have been shown
to promote matrix synthesis in vivo [124–128], and a clinical trial
employing injection of recombinant BMP-7 into the IVD is cur-
rently underway. IL-1 receptor antagonist (IL-1RA) has also been
shown to decrease both cytokine and proteolytic enzyme produc-
tion by NP cells [129,130], with other studies demonstrating simi-
lar effects using anti-TNF therapies [131]. However, the limitation
of such therapies is their short half-life, necessitating repeated
injections [132]. The reduction in viable cells, particularly in late-
stage degeneration, also limits the efficacy of a purely biologic
therapy; thus cell-based tissue engineering/regenerative therapies
have become the primary focus of current research in the field.
5.3. Cell-based therapy for IVD
Cell-based therapies aim to repopulate the IVD and restore
functional tissue through matrix synthesis by implanted cells
and, potentially, beneficial influences on native cells. Autologous
NP cell re-implantation has been shown to retard degenerative
changes in a dog model, and more importantly, a randomized
human clinical trial using this approach demonstrated a clinically
significant decrease in LBP score and retention of hydration and
disc height compared to discectomy alone [2,133]. However, as
the NP is relatively hypocellular, harvesting sufficient cells for re-
implantation may result in complications [134,135] and NP cells
from degenerate discs display increased/premature senescence
[110] and a catabolic phenotype [107,111–113] which make them
unsuitable for transplantation where normal cell function is
required.
5.4. Native IVD progenitors
Increasing evidence suggests the presence of a native progeni-
tor cell population within the IVD of animals and humans [136–
139], although differences in isolation and characterization
methodology mean it is difficult to compare between studies and
a detailed phenotypic profile of any progenitor population(s) is
yet to be established. While promising, work remains to determine
the regenerative potential of any resident progenitor cell popula-
tion. Furthermore Sakai et al. demonstrated that a population of
Tie2+ progenitor cells identified within the human IVD decreased
with both age and degeneration [136], suggesting isolation of suf-
ficient progenitor cell numbers for (re)implantation may be an
obstacle to clinical application.
5.5. MSCs for IVD regeneration
MSCs have been proposed as an ideal cell source for IVD regen-
eration, with an increasing number of studies demonstrating abil-
ity of both BM-MSCs and AD-MSCs to differentiate into an NP-like
phenotype (discogenic differentiation) [140–147]. In vivo studies
have also demonstrated the ability of implanted MSCs to enhance
matrix production, particularly GAG synthesis, and increase disc
height and hydration [148–153], while a small human clinical trial
demonstrated improved pain and disability scores and an increasein water content in the disc 12 months after MSC implantation
[154]. Over recent years the potential of UC-MSCs and WJSCs for
IVD regeneration has also been demonstrated, with these cells
showing differentiation capacity both in vitro and in vivo [155–
160] and the ability to decrease pain scores when implanted in
humans (albeit in a study of only two patients) [158]. Although
these findings demonstrate the huge potential of MSCs for applica-
tion in IVD regeneration, a wide range of questions remain to be
addressed [161,162]. The most notable questions include: Do MSCs
persist following implantation? Do they undergo discogenic differ-
entiation? What is the effect of the microenvironmental niche on
their survival and function? Are MSCs directly responsible for tis-
sue regeneration? Or do they produce bioactive factors that influ-
ence resident cell function as has been shown in other systems?
Early studies on discogenic differentiation of MSCs relied on the
fact that NP cells are ‘chondrocyte-like’ and express chondrogenic
markers such as SOX-9, type II collagen and aggrecan [163]. How-
ever, there are substantial differences in the ECM of the NP and
articular cartilage [164], as well as the ontogeny of NP cells
[165], suggesting a unique phenotype for NP cells compared to
chondrocytes (or AF cells). In 2010 Minogue et al. published the
first phenotypic profile of human NP cells, compared to articular
chondrocytes, with many genes being confirmed by future studies
[166–168]. A recent consensus paper has sought to define the NP
cell phenotype and while the functional significance of many of
the putative markers is unknown, their expression can be used to
define discogenic differentiation of MSCs [169]. Such markers have
allowed the optimization of discogenic differentiation strategies;
most notably the comparison of growth factors to induce
lineage-specific differentiation and the comparison of MSCs iso-
lated from different anatomical locations. While TGFb has conven-
tionally been used to induce discogenic differentiation, growth
differentiation factors 5 (GDF5) and 6 (GDF6) have both been
shown to produce a more appropriate phenotype, with GDF6-
stimulated MSCs demonstrating the largest increases in discogenic
marker genes and secreting the most NP-like ECM in 3D-culture
[140,143,144]. Of note, GDF6-stimulated AD-MSCs produced a
more appropriate matrix than BM-MSCs obtained from the same
donor [140], and given their relative ease of acquisition and high
proliferation rate, AD-MSCs may thus offer the most appropriate
cell source for IVD regeneration.
MSCs have also been shown to communicate with NP cells in a
bidirectional manner during co-culture [147,170,171], suggesting
that in addition to undergoing differentiation and de novo synthe-
sis of ECM, implanted cells may influence NP cell function through
secretion of bioactive factors, such as anabolic growth factors.
Recent evidence suggests that in addition to the secretion of ana-
bolic factors, MSCs possess anti-inflammatory and anti-catabolic
properties, which could be used in the context of disc degeneration
to reduce cytokine levels, thereby modulating the inflammatory
niche, to produce a healthier, non-degenerate phenotype in native
NP cells (Fig. 3). Indeed Tam recently demonstrated increased GAG
content in an experimentally-induced IVD degeneration model fol-
lowing both intradiscal and intravenous UC-MSCs injection, with-
out evidence of engraftment in the latter approach, suggesting
paracrine signaling from the injected cells may be responsible for
the effects demonstrated [160].
5.6. MSC implantation and the IVD niche
The IVD represents the largest avascular structure in the human
body, with the resident cells relying on diffusion of oxygen and
nutrients from blood vessels in adjacent vertebral bodies [172].
NP cells rely mainly on glycolysis to produce energy, with the
resultant lactic acid also being removed by diffusion out of the disc.
Calcification of the end plates, associated with age and degenera-
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Fig. 3. Bi-directional cell interactions following MSC implantation. The degenerate IVD and OA cartilage represent harsh, catabolic microenvironments, with high levels of
cytokine, most notably IL-1 and TNFa. Following implantation MSCs will respond in a paracrine manner by producing a range of growth factors, anti-inflammatory factors
and anti-catabolic factors, which will influence resident articular chondrocytes (AC) or nucleus pulposus (NP) cells to produce a healthier, more anabolic phenotype and
regenerate tissue.
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ic, acidic and nutrient-deprived [173,174]. The disc is also exposed
to regular dynamic loading, which influences both functional and
phenotypic characteristics of the resident NP cells [175]. Abnormal
over-loading or under-loading, as well as asymmetric loading have
all been demonstrated to exert deleterious effects on NP cell viabil-
ity and phenotype [176,177].
Despite preliminary results showing positive effects of cell-
injection strategies for IVD regeneration, detailed basic research
on IVD cells and their niche indicates that transplanted cells are
unable to survive and adapt in the avascular niche of the IVD
[178]. In particular the current evidence suggests that while
hypoxia and load may be beneficial for discogenic differentiation,
high osmolarity and low pH may be deleterious to MSC survival
and function [143,179,180]. How a combination of factorsinfluences MSC fate is yet to be fully elucidated, but may represent
a major challenge for survival and function of implanted cells in a
clinical setting.
5.7. Scaffolds and biomaterials for IVD tissue engineering
Newly transplanted cells are subjected to high mechanical
loads, which may be detrimental to viability or function; however,
such loads can potentially be minimized by temporarily placing a
screw/rod construct that bridges the intervertebral disc. A more
long-term approach that may enhance MSC survival and differen-
tiation post-implantation is incorporation of cells into a biomate-
rial scaffold. Numerous biomaterials have been proposed, with
many investigators focusing on injectable hydrogels in order to
minimize damage to the surrounding AF (as reviewed in
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biphasic scaffolds to engineer whole IVD [183–186], biomaterials
to regenerate the AF [187–189], and functionalized acellular bio-
materials, for example with the chemoattractant SDF-1 to recruit
resident progenitor cells or MSCs to the disc [190]. Production of
mechanically robust, biodegradable, biocompatible and functional-
ized biomaterials, particularly hydrogels, has been a limitation
within the field, although recent studies suggest that development
of a suitable IVD-like biomaterial is an achievable goal [191,192].5.8. Future perspectives
Like articular cartilage, the IVD presents a challenging and com-
plex tissue to regenerate. While the origin of human NP cells is still
debated and the transcriptional machinery underpinning disco-
genic differentiation remains relatively undefined, the elucidation
of a defined NP phenotype has allowed development of method-
ologies to promote lineage-specific discogenic differentiation of
MSCs, which may demonstrate clinical efficacies in future clinical
trials. The fate of implanted cells in the harsh microenvironment
of articular cartilage, and particularly in the degenerate IVD,
remains to be elucidated. Likewise, the mechanism or mechanisms
by which implanted cells induce regeneration, whether it be direct
differentiation or paracrine stimulation of native cells, remains to
be determined.
Such research in the IVD is hampered by the lack of an appropri-
ate animal model, which accurately mimics the microenvironment
of the human IVD [178,193]. However, novel ex vivo whole organ
IVD model systems are being developed [194–196], in which
microenvironmental parameters can theoretically be indepen-
dently controlled, to allow testing of proposed therapies prior to
clinical translation.
Whether cells require pre-conditioning or pre-differentiation
prior to implantation into cartilage or IVD to enhance cell survival
and matrix formation, also requires testing. The requirement for,
and design of, suitable biomaterials which will withstand the
enzyme-rich, mechanically load microenvironments of disease car-
tilage and disc also remains to be elucidated. Evidence suggests
that cell leakage following MSC implantation into the IVD can
cause peripheral osteophyte formation and this highlights the need
for careful design of any cell implantation strategy [197]. Similarly,
chondrogenic differentiation of MSCs for cartilage regeneration has
the potential risk for hypertrophy and ossification and it remains to
be seen whether such events occur in discogenic differentiation
strategies. Such risks may be mitigated through careful selection
of MSC source, with UC-MSCs or WJSCs offering one potential
source, and differentiation strategy. Furthermore, patient selection
will be critical for successful outcome and treatment modality will
depend on stage of disease.
Cell-based therapies for advanced OA, where cartilage eburna-
tion has occurred, remain a challenge and such patients may still
require joint replacement or tissue engineered cartilage. Similarly,
cell implantation approaches may not benefit those with multi-
level disc disease or those with an advanced stage of disc degener-
ation, where the surrounding tissue may have degenerated. In such
circumstances, a tissue engineered, whole IVD replacement may be
more appropriate. However, the rate of advancement in the field of
regenerative medicine suggests these problems may be overcome
through a combination of functional biomaterials, identification
of appropriate cell source and improved differentiation regimens.6. Conclusions
MSC-based therapies offer huge potential to revolutionize the
treatment of cartilage defects and IVD degeneration and theadvances discussed in this manuscript highlight the progress being
made toward clinical translation of such approaches. However, a
wide range of technical hurdles and conceptual challenges must
still be overcome as research progresses in this exciting and rapidly
expanding field. There are still many technical challenges associ-
ated with isolating, expanding, differentiating, and pre-
conditioning MSCs for subsequent implantation into degenerate
joints and the spine. The physiological microenvironment of both
diseased joints and intervertebral discs is likely to be hypoxic,
acidic, deprived of nutrients, and exposed to higher than normal
concentrations of pro-inflammatory cytokines and reactive oxygen
species. Furthermore, MSCs may be exposed to abnormal physical
loads in anatomical structures that have already been biomechan-
ically compromised. Thus future regenerative medicine strategies
will need to address these remaining concerns.7. Contributors
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